Impact of Antithrombin Activity Levels Following Recombinant Antithrombin Gamma Therapy in Patients with Sepsis-Induced Disseminated Intravascular Coagulation

被引:9
|
作者
Akahoshi, Tomohiko [1 ,3 ]
Kaku, Noriyuki [1 ]
Shono, Yuji [1 ]
Yamamoto, Yuzo [1 ]
Takahashi, Keita [2 ]
Iyonaga, Takeshi [1 ]
Momii, Kenta [1 ]
Nishihara, Masaaki [1 ]
Maki, Jun [2 ]
Tokuda, Kentaro [2 ]
Yamaura, Ken [2 ]
机构
[1] Kyushu Univ Hosp, Emergency & Crit Care Ctr, Fukuoka, Japan
[2] Kyushu Univ, Dept Anesthesiol & Crit Care Med, Grad Sch Med Sci, Fukuoka, Japan
[3] Kyushu Univ Hosp, Emergency & Crit Care Ctr, 3 1 1 Maidashi, Higashi ku, Fukuoka 8128582, Japan
关键词
disseminated intravascular coagulation; sepsis; antithrombin activity; recombinant antithrombin gamma; CRITICALLY-ILL PATIENTS; DIAGNOSTIC-CRITERIA; EFFICACY; SAFETY; SUPPLEMENTATION; MULTICENTER; THROMBOMODULIN; HEPARIN;
D O I
10.1177/10760296221135790
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recombinant antithrombin gamma (rAT) is reported as an effective drug for patients with disseminated intravascular coagulation (DIC) in Japan. As the appropriate dose and targeted AT activity remain unknown, this study aimed to determine these aspects for sepsis-induced DIC. Thirty-one patients with septic shock and DIC with AT levels <70% were treated with rAT between May 2018 and December 2020. The recovery rates from DIC were 32.2% and 63.3% on day 3 and 5 post administration, respectively. Recovery and survival rates were significantly higher in patients who achieved AT activity >= 70% or 80% on day 3 post administration. Receiver operating characteristic curve analysis revealed that the cutoff values of post-treatment AT activity on day 3 for 28-day survival and 5-day recovery from DIC were 79.5% and 81.5%, respectively. Patients who did not achieve AT activity >= 80% on day 3 presented a lower base level of AT activity and lower dose supplementation. Our results suggest that targeted AT activity should be at least 70%, and ideally 80%, and sufficient doses to maintain this activity are required to achieve better outcomes.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Impact of Antithrombin Activity Levels Following Recombinant Antithrombin Gamma Therapy in Patients with Sepsis-Induced Disseminated Intravascular Coagulation
    Akahoshi, Tomohiko
    Kaku, Noriyuki
    Shono, Yuji
    Yamamoto, Yuzo
    Takahashi, Keita
    Iyonaga, Takeshi
    Momii, Kenta
    Nishihara, Masaaki
    Maki, Jun
    Tokuda, Kentaro
    Yamaura, Ken
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [2] Impact of Antithrombin Activity Levels Following Recombinant Antithrombin Gamma Therapy in Patients with Sepsis-Induced Disseminated Intravascular Coagulation
    Akahoshi, Tomohiko
    Kaku, Noriyuki
    Shono, Yuji
    Yamamoto, Yuzo
    Takahashi, Keita
    Iyonaga, Takeshi
    Momii, Kenta
    Nishihara, Masaaki
    Maki, Jun
    Tokuda, Kentaro
    Yamaura, Ken
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [3] Optimal Antithrombin Activity Threshold for Initiating Antithrombin Supplementation in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Multicenter Retrospective Observational Study
    Hayakawa, Mineji
    Yamakawa, Kazuma
    Kudo, Daisuke
    Ono, Kota
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2018, 24 (06) : 874 - 883
  • [4] Impact of Antithrombin Supplementation and Concomitant Anticoagulation Therapy in Pediatric Patients With Disseminated Intravascular Coagulation
    Nagafuchi, Hiroyuki
    Eguchi, Yutaka
    Ikeda, Toshiaki
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2019, 25
  • [5] Comparison of Protective Effects of Recombinant Antithrombin Gamma and Plasma-Derived Antithrombin on Sepsis-Induced Disseminated Intravascular Coagulation and Multiple Organ Failure
    Kuroda, Hiromitsu
    Masuda, Yoshiki
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2020, 26
  • [6] ANTITHROMBIN SUPPLEMENTATION AND MORTALITY IN SEPSIS-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION: A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY
    Hayakawa, Mineji
    Kudo, Daisuke
    Saito, Shinjiro
    Uchino, Shigehiko
    Yamakawa, Kazuma
    Iizuka, Yusuke
    Sanui, Masamitsu
    Takimoto, Kohei
    Mayumi, Toshihiko
    Ono, Kota
    Azuhata, Takeo
    Ito, Fumihito
    Yoshihiro, Shodai
    Hayakawa, Katsura
    Nakashima, Tsuyoshi
    Ogura, Takayuki
    Noda, Eiichiro
    Nakamura, Yoshihiko
    Sekine, Ryosuke
    Yoshikawa, Yoshiaki
    Sekino, Motohiro
    Ueno, Keiko
    Okuda, Yuko
    Watanabe, Masayuki
    Tampo, Akihito
    Saito, Nobuyuki
    Kitai, Yuya
    Takahashi, Hiroki
    Kobayashi, Iwao
    Kondo, Yutaka
    Matsunaga, Wataru
    Nachi, Sho
    Miike, Toru
    Takahashi, Hiroshi
    Takauji, Shuhei
    Umakoshi, Kensuke
    Todaka, Takafumi
    Kodaira, Hiroshi
    Andoh, Kohkichi
    Kasai, Takehiko
    Iwashita, Yoshiaki
    Arai, Hideaki
    Murata, Masato
    Yamane, Masahiro
    Shiga, Kazuhiro
    Hori, Naoto
    SHOCK, 2016, 46 (06): : 623 - 631
  • [7] The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation
    Iba, Toshiaki
    Saitoh, Daizoh
    Gando, Satoshi
    Thachil, Jecko
    THROMBOSIS RESEARCH, 2015, 135 (05) : 897 - 901
  • [8] Effects of combination therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation
    Iba, Toshiaki
    Hagiwara, Akiyoshi
    Saitoh, Daizoh
    Anan, Hideaki
    Ueki, Yutaka
    Sato, Koichi
    Gando, Satoshi
    ANNALS OF INTENSIVE CARE, 2017, 7
  • [9] Supplemental dose of antithrombin use in disseminated intravascular coagulation patients after abdominal sepsis
    Tagami, Takashi
    Matsui, Hiroki
    Fushimi, Kiyohide
    Yasunaga, Hideo
    THROMBOSIS AND HAEMOSTASIS, 2015, 114 (03) : 537 - 545
  • [10] Benefit Profile of Thrombomodulin Alfa Combined with Antithrombin Concentrate in Patients with Sepsis-Induced Disseminated Intravascular Coagulation
    Murao, Atsushi
    Kato, Takayuki
    Yamane, Tetsunobu
    Honda, Goichi
    Eguchi, Yutaka
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28